Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo.
Explore this paper's citation graph
Summary
If confirmed in clinical trials, this antiproliferative action of vasoactive intestinal peptide may offer a new and promising means of suppressing SCLC in human subjects, without the toxic side effects of chemotherapeutic agents.
- Type
- article
- Published
- 1998-11-24
- Cited by
- 54
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W1964999053
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:34929148
Keywords
Vasoactive intestinal peptide, Forskolin, Cell growth, In vivo, Intracellular
References
- Secretin/vasoactive intestinal peptide-stimulated secretion of bombesin/gastrin releasing peptide from human small cell carcinoma of the lung.
- Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties.
- Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.
- Protein measurement with the Folin phenol reagent.
- Establishment and identification of small cell lung cancer cell lines having classic and variant features.
- Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture.
- Definition of a tumor suppressor locus within human chromosome 3p21-p22.
- Small-cell lung carcinoma: inhibition of proliferation by vasoactive intestinal peptide and helodermin and enhancement of inhibition by anti-bombesin antibody.
- Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
- Clonogenic cell assay for anchorage‐dependent squamous carcinoma cell lines using limiting dilution
- A critical appraisal of the "human tumor stem-cell assay".
- Suppression of meiosis of male germ cells by an antagonist of luteinizing hormone-releasing hormone.
- A femtomolar-acting neuroprotective peptide.
- A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
- [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo.
- Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
- Polypeptide with Broad Biological Activity: Isolation from Small Intestine
- Pituitary adenylate cyclase activating polypeptide receptors are present on small cell lung cancer cells
- Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
- Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines.
Cited by
- VPAC receptors as target for anti-cancer drug delivery
- VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens.
- Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion.
- Increased VIP Receptor Expression Mediates CFTR Membrane Localization in Response to VIP Treatment in VIP Knockout Mice
- Implication du système VIP-récepteurs dans la migration et l'invasion in vitro de cellules de glioblastome humain
- Extrapituitary effects of the growth hormone-releasing hormone.
- VIP as a trophic factor in the CNS and cancer cells.
- Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro.
- Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormone-releasing hormone antagonists
- Synthesis and conformational studies of 3,4-di-O-acylated furanoid sugar amino acid-containing analogs of the receptor binding inhibitor of vasoactive intestinal peptide
- In vitro and in vivo treatment of colon cancer by VIP antagonists.
- A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines
- Expression and fine mapping of murine vasoactive intestinal peptide receptor 1
- Immunohistochemical and Immunochemical Evidence for Exprssion of Human Lung PACAP/VIP Receptors
- Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung.
- Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes
- Immunocytochemical Identification of VPAC1, VPAC2, and PAC1 Receptors in Normal and Neoplastic Human Tissues with Subtype-Specific Antibodies
- VIP receptor 1 (VPAC1) promoter targets the expression of a reporter gene to cerebellum and adrenal medulla in transgenic mice.
- Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity
- Conformational studies of 3,4-dideoxy furanoid sugar amino acid containing analogs of the receptor binding inhibitor of vasoactive intestinal peptide
Related papers
- Effect of novel 7 beta-derivatives of forskolin upon human platelet adenylate cyclase system.
- Activation of hormone‐sensitive adenylate cyclase by forskolin
- Forskolin, adenylate cyclase, and cell physiology: an overview.
- Adenylate cyclase activity as a function of forskolin concentration.
- Forskolin as a probe of adenylate cyclase of adipocytes.
- Forskolin as an activator of adenylate cyclase complex of differentiating erythroid bone-marrow cells.
- Effect of thuringiensin on adenylate cyclase in rat cerebral cortex.
- Desensitization in rat parotid to beta-adrenergic agonists and counteracting effects of forskolin are conserved in membrane and detergent-solubilized adenylate cyclase catalyst activity.
- Interaction of forskolin with resolved adenylate cyclase components.